Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%

Healthcare

Page 40
  1. Mar 31, 2026 · 07:45 · NGEN

    Clinical Validation Confirmed, Capital Runway Tightens Ahead of Phase 3 Pivot

    NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

    01
  2. Mar 31, 2026 · 07:30 · CTX

    Crescita Locks $0.80 Buyout as Q4 Earnings Validate Manufacturing Pivot

    Crescita Reports Q4 and Fiscal 2025 Results

    02
  3. Mar 31, 2026 · 07:01 · FNDX

    FendX Pivots to Liquid Coatings and Settles Debt in Shares as Stock Tests Lows

    FendX Provides Corporate Update

    03
  4. Mar 31, 2026 · 07:00 · TELO

    Telo Genomics Swaps Founder for Veteran CEO as Cash Burn Outpaces Clinical Validation

    Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

    04
  5. Mar 31, 2026 · 07:00 · VITA

    Vitalist Bets on Medical AI Acquisition While Cash Reserves Dwindle and Debt Looms

    Vitalist Inc. Expands Global Wearable Footprint via Acquisition of Somatix, Adding Medical Grade AI and Remote Patient Monitoring to VitalOS(TM)

    05
  6. Mar 31, 2026 · 06:31 · CHS

    CHS Pitches $20M Pipeline and AI Upgrades as Capital Extension Looms

    Comprehensive Healthcare Systems Provides Business Development Update Highlighting Expanding Pipeline and Operational Enhancements

    06
  7. Mar 31, 2026 · 06:31 · THRM

    [Value]

    Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually

    07
  8. Mar 31, 2026 · 03:00 · INNO

    Insider Debt Bridges Runway as Core Revenue Slips Ahead of Uncertain U.S. Uplisting

    Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M

    08
  9. Mar 30, 2026 · 18:07 · QNTM

    Court Clears Path for $700M Spoofing Suit, But Cash Burn and Clinical Execution Remain the Real Hurdles

    Quantum Biopharma signs LOI for phase 2 MS trial

    09
  10. Mar 30, 2026 · 16:59 · MRVL

    Marvel obtains Alberta funding for MB-204 phase I

    Marvel obtains Alberta funding for MB-204 phase I

    10
  11. Mar 30, 2026 · 16:52 · VIVI

    Tempramed signs LOI for Panama distribution expansion

    Tempramed signs LOI for Panama distribution expansion

    11
  12. Mar 30, 2026 · 11:15 · BNXT

    Bionxt developing sublingual semaglutide ODF system

    Bionxt developing sublingual semaglutide ODF system

    12
  13. Mar 30, 2026 · 07:50 · QNTM

    Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

    Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

    13
  14. Mar 30, 2026 · 07:30 · MRVL

    Non-Dilutive Capital Fuels Phase I Leap as Patent Moat Tightens

    Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204

    14
← Newer Older →